Your browser doesn't support javascript.
loading
Early HER2-positive breast cancer arising from a fibroadenoma: a case report.
Fujimoto, Akihiro; Matsuura, Kazuo; Kawasaki, Tomonori; Ichinose, Yuki; Nukui, Asami; Hiratsuka, Miyuki; Asano, Aya; Shimada, Hiroko; Osaki, Akihiko; Saeki, Toshiaki.
Afiliação
  • Fujimoto A; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Matsuura K; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Kawasaki T; Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Ichinose Y; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Nukui A; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Hiratsuka M; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Asano A; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Shimada H; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Osaki A; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Saeki T; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Oxf Med Case Reports ; 2021(9): omab083, 2021 Sep.
Article em En | MEDLINE | ID: mdl-34527256
ABSTRACT
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a case of HER2-positive breast cancer arising from FA that was treated with chemotherapy plus anti-HER2 therapy. In this early case, upfront surgery outcomes guided the selection of appropriate systemic therapy. A 31-year-old woman previously diagnosed with FA experienced tumor growth. Core needle biopsy and imaging studies confirmed a diagnosis of stage IIA HER2-positive invasive ductal carcinoma (IDC) with no evidence of lymph node metastasis (cT2N0M0). Breast-conserving surgery was performed. Pathological diagnosis revealed stage IA IDC with a predominant intraductal component (pT1aN0M0), arising from FA. In conclusion, we encountered an extremely rare case of HER2-positive breast cancer arising from FA in which pathological infiltration was difficult to predict based on preoperative imaging.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article